p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
暂无分享,去创建一个
M. Willingham | M. Brechbiel | R. Haynes | R. Abeysinghe | B. Greene | J. Turner | R. Planalp | F. Torti | S. Torti | R. Haynes | Jolyn Turner
[1] Yoichi Taya,et al. Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.
[2] Catherine Méplan,et al. Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells , 2000, Oncogene.
[3] G. Lescoat,et al. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. , 2000, Carcinogenesis.
[4] K. Vousden,et al. Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.
[5] M. Willingham. Cytochemical Methods for the Detection of Apoptosis , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[6] M. Ishidate,et al. APOPTOSIS DURING IRON CHELATOR‐INDUCED DIFFERENTIATION IN F9 EMBRYONAL CARCINOMA CELLS , 1999, Cell biology international.
[7] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. , 1999, Blood.
[8] K. Vousden,et al. Mechanisms of p53-mediated apoptosis , 1999, Cellular and Molecular Life Sciences CMLS.
[9] M. Gassmann,et al. Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.
[10] D. Lane,et al. The p53 tumour suppressor gene , 1998, The British journal of surgery.
[11] Moshe Oren,et al. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs , 1998, Oncogene.
[12] M. Brechbiel,et al. Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties , 1998, JBIC Journal of Biological Inorganic Chemistry.
[13] M. Brechbiel,et al. Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.
[14] K. Vousden,et al. Characterization of Structural p53 Mutants Which Show Selective Defects in Apoptosis but Not Cell Cycle Arrest , 1998, Molecular and Cellular Biology.
[15] L. Neckers,et al. Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.
[16] D. Naidoo,et al. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. , 1998, Cancer research.
[17] S. Nagata,et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.
[18] S. Nagata,et al. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 1998, Nature.
[19] W. El-Deiry,et al. Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.
[20] D. Givol,et al. Induced p 53 expression in lung cancer cell line promotes cell senescence and di erentially modi ® es the cytotoxicity of anti-cancer drugs , 1998 .
[21] D. Richardson. Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.
[22] J N Weinstein,et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.
[23] G. Prendergast,et al. The polyproline region of p53 is required to activate apoptosis but not growth arrest , 1997, Oncogene.
[24] Cynthia A. Schandl,et al. Major DNA Fragmentation Is a Late Event in Apoptosis , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[25] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.
[26] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[27] Yi Sun,et al. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound , 1997, Oncogene.
[28] J. Kemp,et al. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. , 1997, Histology and histopathology.
[29] J. Kemp,et al. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. , 1997, Pathobiology : journal of immunopathology, molecular and cellular biology.
[30] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[31] R. Evans,et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Brechbiel,et al. An improved synthesis of cis,cis-1,3,5-triaminocyclohexane. Synthesis of novel hexadentate ligand derivatives for the preparation of gallium radiopharmaceuticals , 1996 .
[33] J C Reed,et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.
[34] R. Cozza,et al. Role of deferoxamine in tumor therapy. , 1996, Acta haematologica.
[35] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.
[36] J. Kemp,et al. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. , 1995, Cancer research.
[37] R. Haq,et al. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. , 1995, Experimental hematology.
[38] A. Hoffbrand,et al. Iron chelators induce apoptosis in proliferating cells , 1995, British journal of haematology.
[39] R Montesano,et al. Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.
[40] D. Fisher. Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.
[41] P. Walker,et al. Detection of the initial stages of DNA fragmentation in apoptosis. , 1993, BioTechniques.
[42] P. Hainaut,et al. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. , 1993, Cancer research.
[43] M. Fritsche,et al. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. , 1993, Oncogene.
[44] R. Rubin,et al. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice , 1992, Cancer.
[45] R. Hider,et al. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.
[46] A. Levine,et al. The p53 tumour suppressor gene , 1991, Nature.
[47] J. Kemp,et al. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor. , 1990, Blood.
[48] A. Donfrancesco,et al. Effects of a single course of deferoxamine in neuroblastoma patients. , 1990, Cancer research.
[49] R. Hider,et al. 2 The development of iron chelating drugs , 1989 .
[50] R. Hider,et al. The development of iron chelating drugs. , 1989, Bailliere's clinical haematology.
[51] H. Munro,et al. Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[52] E. Weinberg. Iron withholding: a defense against infection and neoplasia. , 1984, Physiological reviews.
[53] M. Freedman,et al. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. , 1984, Blood.
[54] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[55] W. Faulk,et al. TRANSFERRIN AND TRANSFERRIN RECEPTORS IN CARCINOMA OF THE BREAST , 1980, The Lancet.